Physician

Rabia Parveez, MD

According to 2025 Medicare claims, Rabia Parveez, MD (NPI: 1922055680) practices hematology/oncology in the Fresno, CA market, with the plurality of this provider's patient population coming from Fresno, CA. This provider's primary affiliated billing organization is CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (NPI: 1083661607; TIN: 770324589) and primary practice location at 93720-3347.

Parveez's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 783 traditional Medicare patients, billed 252,171 HCPCS/CPT codes, and received $3,424,753 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,199 prescription claims across 154 beneficiaries totaling $2,817,294 in drug costs, led by Cabometyx (Cabozantinib S-Malate). DME data shows 11 claims. Open Payments data shows 88 records totaling $1,916. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,668,991 to $3,424,753. Similarly, Part D prescription costs have moved sharply higher in recent years, from $614,656 to $2,817,294. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.8M$3.5M2015 Medicare payment: $1,668,991 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $1,670,334 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $1,737,216 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $1,977,384 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $1,969,257 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $2,648,399 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $2,910,043 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $3,539,202 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $2,564,707 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $3,424,753 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015645371,766$1,668,991
2016820340,874$1,670,334
2017748313,237$1,737,216
2018758286,182$1,977,384
2019587273,852$1,969,257
2020895326,657$2,648,399
2021975353,006$2,910,043
2022871350,437$3,539,202
2023836263,062$2,564,707
2024783252,171$3,424,753

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$1.4M$2.8M2015 Drug cost: $614,656 (USD; Tot_Drug_Cst)2016 Drug cost: $695,721 (USD; Tot_Drug_Cst)2017 Drug cost: $622,694 (USD; Tot_Drug_Cst)2018 Drug cost: $744,734 (USD; Tot_Drug_Cst)2019 Drug cost: $983,526 (USD; Tot_Drug_Cst)2020 Drug cost: $1,300,611 (USD; Tot_Drug_Cst)2021 Drug cost: $1,155,826 (USD; Tot_Drug_Cst)2022 Drug cost: $1,899,529 (USD; Tot_Drug_Cst)2023 Drug cost: $2,203,471 (USD; Tot_Drug_Cst)2024 Drug cost: $2,817,294 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20151531,270$614,656
20161321,149$695,721
20171281,067$622,694
20181451,121$744,734
20191651,230$983,526
20201691,215$1,300,611
20211731,289$1,155,826
20221741,432$1,899,529
20231691,351$2,203,471
20241541,199$2,817,294

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

DME Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: DME_Suplr_Mdcr_Pymt_Amt. Source: Medicare DME, Devices & Supplies by Referring Provider.0$2.8K$5.6K2015 Medicare payment: $5,558 (USD; DME_Suplr_Mdcr_Pymt_Amt)2016 Medicare payment: $4,814 (USD; DME_Suplr_Mdcr_Pymt_Amt)2017 Medicare payment: $226 (USD; DME_Suplr_Mdcr_Pymt_Amt)2019 Medicare payment: $950 (USD; DME_Suplr_Mdcr_Pymt_Amt)2020 Medicare payment: $2,017 (USD; DME_Suplr_Mdcr_Pymt_Amt)2021 Medicare payment: $5,481 (USD; DME_Suplr_Mdcr_Pymt_Amt)2022 Medicare payment: $2,577 (USD; DME_Suplr_Mdcr_Pymt_Amt)2023 Medicare payment: $2,529 (USD; DME_Suplr_Mdcr_Pymt_Amt)2024 Medicare payment: $1,968 (USD; DME_Suplr_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClaimsPayment
2015N/R106$5,558
2016N/R57$4,814
2017N/R12$226
2018N/RN/RN/R
2019N/R11$950
20201216$2,017
20211154$5,481
20221216$2,577
20231116$2,529
2024N/R11$1,968

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more362791$97
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more246331$64
80053Blood test, comprehensive group of blood chemicals3921,021$10
36415Insertion of needle into vein for collection of blood sample4211,601$9
85025Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count4211,634$8

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
CabometyxCabozantinib S-Malate26780$626,090
TibsovoIvosidenib12360$388,146
BrukinsaZanubrutinib21615$302,035
OrserduElacestrant Hcl11330$238,411
JakafiRuxolitinib Phosphate17510$199,537

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS CodeHCPCS DescriptionSupplier Rental IndicatorTotal Supplier BeneficiariesTotal Supplier ClaimsTotal Medicare Payment Amount
L8000Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any typeNN/R11$1,968

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.88$1,916AstraZeneca Pharmaceuticals LP
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Rabia Parveez, MD?

Tedicare shows public-source Medicare data for Rabia Parveez, MD (NPI 1922055680), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rabia Parveez, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Rabia Parveez, MD?

Rabia Parveez, MD is linked to CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (billing NPI 1083661607) in the available physician profile data.

Does Rabia Parveez, MD have Open Payments data?

Rabia Parveez, MD has 88 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.